James Waldron

AstraZeneca has returned to recent licensing partner CSPC Pharmaceuticals with

Once hailed as the future of immuno-oncology, it’s been a tough few months for any remaining fans of anti-TIGIT antibodies.

KalVista Pharmaceuticals has become the latest biotech to face delays to the FDA's decision-making, as the agency apparently blames a “heavy workload” for pushing back a PDUFA date.

A South Korean biotech's GLP-1 candidate has reduced liver fat in patients with metabolic dysfunction-associated steatohepatitis (MASH), with the added benefit of helping patients lose weight.

KalVista Pharmaceuticals has become the latest biotech to face delays to the FDA’s decision-making, as the agency apparently blames a “heavy workload” for pushing back a PDUFA date.

NextCure has ramped up its antibody-drug conjugate pivot, penning a $745 million deal for the ex-China rights to Simcere Zaiming's phase 1-stage tumor asset.

Eli Lilly is in talks to buy gene editing partner Verve Therapeutics for up to $1.3 billion, according to a report in the Financial Times

Aptose Biosciences has been thrown a financial lifeline by its own CEO while the leukemia-focused biotech scrambles around for cash to prevent the company from going bust.

Prothena is laying off almost two-thirds of its workforce as the Irish biotech navigates the fallout from giving up on its failed amyloidosis drug.

Life sciences investment firm Syncona has blamed the “particularly challenging” market conditions for shifting its strategy away from early-stage biotechs and focusing on companies likely to offer near-term rewards.